Skip to main content


Page 2 of 17

  1. Substance use in women is associated with unique psycho-social and physical vulnerabilities and poses complex challenges during pregnancy and motherhood. Gender-sensitive drug policy which considers the needs ...

    Authors: Abhishek Ghosh, Dijana Jerkovic, Liljana Aleksandar Ignjatova, Carla Bruguera, Dalia I. Ibrahim, Katarzyna Okulicz-Kozaryn, J. Maphisa Maphisa, Thomas F. Martinelli, Ana Neto, Joana Canedo and Rebecca Gordon
    Citation: Addiction Science & Clinical Practice 2023 18:53
  2. Research suggests peer support groups can amplify and extend treatment effects and enhance long-term recovery from Alcohol and Other Drug (AOD) problems. However, they are rarely integrated into outpatient tre...

    Authors: V. Manning, A. D. Roxburgh and M. Savic
    Citation: Addiction Science & Clinical Practice 2023 18:52
  3. We use a novel, longitudinal approach to describe average time spent in opioid use disorder (OUD) cascade of care stages for people with HIV (PWH) and with OUD, incorporating four definitions of treatment rete...

    Authors: Jarratt D. Pytell, Anthony T. Fojo, Jeanne C. Keruly, LaQuita N. Snow, Oluwaseun Falade-Nwulia, Richard D. Moore, Geetanjali Chander and Catherine R. Lesko
    Citation: Addiction Science & Clinical Practice 2023 18:51
  4. In studies of the general population and of military veterans, many primary care patients with hazardous drinking and PTSD and/or depression (abbreviated here as HD +) do not initiate or engage with alcohol-re...

    Authors: Michael A. Cucciare, Kathy Marchant, Cristy Benton, Deanna Hildebrand, Sharfun Ghaus, Xiaotong Han, Ronald G. Thompson and Christine Timko
    Citation: Addiction Science & Clinical Practice 2023 18:50
  5. A valid opioid use disorder (OUD) identification algorithm for use in administrative medical record data would enhance investigators’ ability to study consequences of OUD, OUD treatment seeking and treatment o...

    Authors: Jeffrey F. Scherrer, Mark D. Sullivan, Marc R. LaRochelle and Richard Grucza
    Citation: Addiction Science & Clinical Practice 2023 18:49
  6. An emerging public health threat of methamphetamine/opioid co-use is occurring in North America, including increases in overdoses related to concomitant methamphetamine/opioid use. This presents a potential ri...

    Authors: Cayley Russell, Justine Law, Sameer Imtiaz, Jürgen Rehm, Bernard Le Foll and Farihah Ali
    Citation: Addiction Science & Clinical Practice 2023 18:48
  7. We examined acceptability of and preferences for potential medications for treating methamphetamine use disorder (MUD) among people who use methamphetamine and examined how benefits and drawbacks of methamphet...

    Authors: Karla D. Wagner, Charles Marks, Phillip Fiuty, Robert W. Harding and Kimberly Page
    Citation: Addiction Science & Clinical Practice 2023 18:47
  8. A minority of all individuals with alcohol use disorders (AUD) seek treatment, where stigma is one prominent barrier. Social support is important to facilitate health and increase treatment-seeking. Whether th...

    Authors: Sara Wallhed Finn, Anna Mejldal and Anette Søgaard Nielsen
    Citation: Addiction Science & Clinical Practice 2023 18:46
  9. Pharmacy administration and dispensing of methadone treatment for opioid use disorder (PADMOUD) may address inadequate capability of opioid treatment programs (OTPs) in the US by expanding access to methadone ...

    Authors: Li-Tzy Wu, William S. John, Paolo Mannelli, Eric D. Morse, Alyssa Anderson and Robert P. Schwartz
    Citation: Addiction Science & Clinical Practice 2023 18:45
  10. Motivational enhancement therapy (MET) has shown to be efficacious as treatment of alcohol use disorder (AUD), in reducing alcohol consumption and related consequences. However, qualitative research on how pat...

    Authors: Stina Ingesson Hammarberg, Jennie Sundbye, Rebecca Tingvall, Anders Hammarberg and Christina Nehlin
    Citation: Addiction Science & Clinical Practice 2023 18:44
  11. Use of benzodiazepines (BZD) in patients receiving opioid agonist treatment (OAT) is common and associated with a variety of negative health and social outcomes. This cross-sectional study investigates the imp...

    Authors: Maximilian Meyer, Ferdinand Gygli, Jean N. Westenberg, Otto Schmid, Johannes Strasser, Undine E. Lang, Kenneth M. Dürsteler and Marc Vogel
    Citation: Addiction Science & Clinical Practice 2023 18:43
  12. Acute care inpatient admissions outside of psychiatric facilities have been increasingly identified as a critical touchpoint for opioid use disorder (OUD) treatment. We sought to describe non-opioid overdose h...

    Authors: Sudha R. Raman, Cassie B. Ford, Bradley G. Hammill, Amy G. Clark, Dana C. Clifton and George L. Jackson
    Citation: Addiction Science & Clinical Practice 2023 18:42
  13. Extant literature is limited on adoption of evidence-based harm reduction strategies in hospitals. We explored patient perceptions of incorporating harm reduction supplies and education in hospital care with p...

    Authors: Rachel French, M. Holliday Davis, Shoshana V. Aronowitz, Molly Crowe, Matthew Abrams, Grace Edwards and Margaret Lowenstein
    Citation: Addiction Science & Clinical Practice 2023 18:41
  14. Syringe services programs (SSPs) provide a spectrum of health services to people who use drugs, with many providing referral and linkage to substance use disorder (SUD) treatment, and some offering co-located ...

    Authors: Andrea Jakubowski, Sabrina Fowler and Aaron D. Fox
    Citation: Addiction Science & Clinical Practice 2023 18:40
  15. Breaking Free Online (BFO), a computer-assisted therapy (CAT) program for substance use disorders (SUD), has been available across UK treatment services for the past decade and has demonstrated efficacy. The C...

    Authors: Sarah Elison-Davies, Lauren Pittard, Tracey Myton, Andrew Jones, Jonathan Ward and Glyn Davies
    Citation: Addiction Science & Clinical Practice 2023 18:39
  16. Hospitalizations are a vital opportunity for the initiation of life-saving opioid agonist therapy (OAT) for patients with opioid use disorder. A novel approach to OAT initiation is the use of IV buprenorphine ...

    Authors: John P. Murray, Geoffrey Pucci, George Weyer, Mim Ari, Sarah Dickson and Angela Kerins
    Citation: Addiction Science & Clinical Practice 2023 18:38
  17. Individuals who have substance use disorders may have an elevated risk of suicidality. This study sought to examine the prevalence of, and identify factors associated with, suicidality in adults with opioid us...

    Authors: Michelle R. Lent, Karen L. Dugosh, Emily Hurstak, Hannah R. Callahan and Kimberly Mazur
    Citation: Addiction Science & Clinical Practice 2023 18:37
  18. Music therapy has been shown to be effective for multiple clinical endpoints associated with substance use disorder such as craving reduction, emotion regulation, depression, and anxiety, but there are a lack ...

    Authors: Jörg Fachner, Clemens Maidhof, Daniel Murtagh, Devon De Silva, Filippo Pasqualitto, Paul Fernie, Francesca Panin, Andrew Michell, Leonardo Muller-Rodriguez and Helen Odell-Miller
    Citation: Addiction Science & Clinical Practice 2023 18:36
  19. Hepatitis C virus (HCV) transmission is primarily driven by injection drug use, and acute HCV infection rates are increased in rural communities with substantial barriers to care. Treatment of HCV in persons w...

    Authors: Megan C. Herink, Andrew Seaman, Gillian Leichtling, Jessica E. Larsen, Tonhi Gailey, Ryan Cook, Ann Thomas and P. Todd Korthuis
    Citation: Addiction Science & Clinical Practice 2023 18:35
  20. Concomitant with low rates of pharmacotherapy for incarcerated individuals with OUD, there is a high rate of opioid overdose following re-entry into the community. Our research objective was to develop a bette...

    Authors: Techna Cadet, Ali Jalali, Philip J. Jeng, Sabrina Poole, George Woody and Sean M. Murphy
    Citation: Addiction Science & Clinical Practice 2023 18:34
  21. This study examined associations between receipt of hepatitis C (HCV) treatment and retention in office-based opioid treatment (OBOT) care.

    Authors: Mary L. Geist, Andrea C. Radick, Judith I. Tsui, Kendra L. Blalock, Addy Adwell, Elsabeth Tamru, Nancy C. Connolly and Jocelyn R. James
    Citation: Addiction Science & Clinical Practice 2023 18:33
  22. Smokeless tobacco (SLT) products are gaining popularity around the globe, particularly in Asia, Africa, and the Middle East. Among these products, Nass (aka Naswar) is popular among the Turkmen ethnicity in Ir...

    Authors: Bagher Pahlavanzadeh, Shohreh Kolagari, Mohammad Ebrahimi Kalan, Ziyad Ben Taleb, Kenneth D. Ward, Samane Zare and Abdurrahman Charkazi
    Citation: Addiction Science & Clinical Practice 2023 18:32
  23. Hospital-based clinicians infrequently initiate medications for opioid use disorder (MOUD) for hospitalized patients. Our objective was to understand hospital-based clinicians’ knowledge, comfort, attitudes, a...

    Authors: Andrea Jakubowski, Sumeet Singh-Tan, Kristine Torres-Lockhart, Shadi Nahvi, Melissa Stein, Aaron D. Fox and Tiffany Lu
    Citation: Addiction Science & Clinical Practice 2023 18:31
  24. SMART (Self-Management and Recovery Training) Recovery is a mutual-aid program informed by cognitive behaviour therapy and motivational interviewing that provides support for a range of addictive behaviours. S...

    Authors: Alistair Lum, Despoina Damianidou, Kylie Bailey, Stephanie Cassel, Katherine Unwin, Alison Beck, Peter J. Kelly, Angela Argent, Frank P. Deane, Sophie Langford, Amanda L. Baker and Kristen McCarter
    Citation: Addiction Science & Clinical Practice 2023 18:30
  25. Approximately 400,000 people who smoke cigarettes survive Acute Coronary Syndrome (ACS; unstable angina, ST and non-ST elevation myocardial infarction) each year in the US. Continued smoking following ACS is a...

    Authors: Melissa Adkins-Hempel, Sandra J. Japuntich, Michelle Chrastek, Shira Dunsiger, Christopher E. Breault, Woubeshet Ayenew, Susan A. Everson-Rose, Prabhjot S. Nijjar, Beth C. Bock, Wen-Chih Wu, Michael D. Miedema, Brett M. Carlson and Andrew M. Busch
    Citation: Addiction Science & Clinical Practice 2023 18:29
  26. Although the detrimental health effects of alcohol are well established, consumption levels are high in many high-income countries such as Germany. Improving alcohol health literacy presents an integrated appr...

    Authors: Jakob Manthey, Daša Kokole, Steffi Riedel-Heller, Gill Rowlands, Ingo Schäfer, Georg Schomerus, Renate Soellner and Carolin Kilian
    Citation: Addiction Science & Clinical Practice 2023 18:28
  27. Alcohol use disorders (AUD) are prevalent and often go untreated. Patients are commonly screened for AUD in primary care, but existing treatment programs are failing to meet demand. Digital therapeutics includ...

    Authors: Jessica M. Mogk, Theresa E. Matson, Ryan M. Caldeiro, Angela M. Garza Mcwethy, Tara Beatty, Brandie C. Sevey, Clarissa W. Hsu and Joseph E. Glass
    Citation: Addiction Science & Clinical Practice 2023 18:27
  28. Most people with opioid use disorder (OUD) have co-occurring substance use, which is associated with lower receipt of OUD medications (MOUD). Expanding MOUD provision and care linkage outside of substance use ...

    Authors: Madeline C. Frost, Elena M. Soyer, Carol E. Achtmeyer, Eric J. Hawkins, Joseph E. Glass, Kevin A. Hallgren and Emily C. Williams
    Citation: Addiction Science & Clinical Practice 2023 18:26
  29. Individuals with substance use disorder (SUD) have high prevalence of cigarette smoking and difficulty quitting. Peer recovery coaches (PRCs; individuals with lived SUD experience) facilitate SUD behavior chan...

    Authors: Joanna M. Streck, Susan Regan, Michael Werner, Alexia Glynn, Andrea C. Villanti, Elyse R. Park, Sarah E. Wakeman, A. Eden Evins and Nancy A. Rigotti
    Citation: Addiction Science & Clinical Practice 2023 18:25
  30. National opioid-related overdose fatalities totaled 650,000 from 1999 to 2021. Some of the highest rates occurred in New Hampshire, where 40% of the population lives rurally. Medications for opioid use disorde...

    Authors: Owen B. Murray, Marcy Doyle, Bethany M. McLeman, Lisa A. Marsch, Elizabeth C. Saunders, Katherine M. Cox, Delitha Watts and Jeanne Ryer
    Citation: Addiction Science & Clinical Practice 2023 18:24
  31. The opioid overdose and polysubstance use crises have led to the development of low-barrier, transitional substance use disorder (SUD) treatment models, including bridge clinics. Bridge clinics offer immediate...

    Authors: Jessica L. Taylor, Sarah E. Wakeman, Alexander Y. Walley and Laura G. Kehoe
    Citation: Addiction Science & Clinical Practice 2023 18:23
  32. Attempts to routinely embed brief interventions in health systems have long been challenging, with healthcare professionals concerned about role adequacy, legitimacy, and support. This is the first study to ex...

    Authors: Mary Madden, Duncan Stewart, Thomas Mills and Jim McCambridge
    Citation: Addiction Science & Clinical Practice 2023 18:22
  33. Federal and state regulations require frequent direct observation of methadone ingestion at an Opioid Treatment Program (OTP)—a requirement that creates barriers to patient access. Video observed therapy (VOT)...

    Authors: James B. Darnton, Elenore P. Bhatraju, Kristin Beima-Sofie, Alyssa Michaels, Kevin A. Hallgren, Sean Soth, Paul Grekin, Steve Woolworth and Judith I. Tsui
    Citation: Addiction Science & Clinical Practice 2023 18:21
  34. Medications for opioid use disorder (MOUD) are associated with positive health outcomes. People remaining on MOUD have a reduced likelihood of drug overdose and mortality. Tanzania supports a national opioid t...

    Authors: Deja Knight, Iddi Haruna Nkya, Nora Solon West, Cui Yang, Michael Kidorf, Carl Latkin and Haneefa T. Saleem
    Citation: Addiction Science & Clinical Practice 2023 18:19
  35. Despite the frequent comorbidity of substance use disorders (SUDs) and psychiatric disorders, it remains unclear if screening for substance use in behavioral health clinics is a common practice. The aim of thi...

    Authors: Diana Woodward, Timothy E. Wilens, Meyer Glantz, Vinod Rao, Colin Burke and Amy M. Yule
    Citation: Addiction Science & Clinical Practice 2023 18:18
  36. Alcohol and cannabis are the most commonly used substances among adolescents in the U.S. The consequences related to using both substances together are significantly higher relative to use of either substance ...

    Authors: Karen Chan Osilla, Elizabeth J. D’Amico, Rosanna Smart, Anthony Rodriguez, Katherine Nameth and Justin Hummer
    Citation: Addiction Science & Clinical Practice 2023 18:17
  37. During the period of community re-entry immediately following release from jail or prison, individuals with opioid use disorder (OUD) face structural barriers to successful re-entry and high risk of overdose. ...

    Authors: Kim A. Hoffman, Emma Thompson, Marina Gaeta Gazzola, Lindsay M. S. Oberleitner, Anthony Eller, Lynn M. Madden, Ruthanne Marcus, David E. Oberleitner, Mark Beitel and Declan T. Barry
    Citation: Addiction Science & Clinical Practice 2023 18:16
  38. Heroin-assisted treatment (HAT) is a proven effective treatment option for individuals with severe opioid use disorder (OUD). In Switzerland, pharmaceutical heroin (diacetylmorphine, DAM) is available in table...

    Authors: Jean N. Westenberg, Maximilian Meyer, Johannes Strasser, Michael Krausz, Kenneth M. Dürsteler, Luis Falcato and Marc Vogel
    Citation: Addiction Science & Clinical Practice 2023 18:15
  39. Managed alcohol programs aim to reduce health and social harms associated with severe alcohol use disorder. Here, we describe a young man with severe alcohol use disorder enrolled in a managed alcohol program,...

    Authors: Thomas D. Brothers, Alexander Y. Walley, Helen Rivers-Bowerman, Magnus McLeod and Leah Genge
    Citation: Addiction Science & Clinical Practice 2023 18:14
  40. Patients with opioid use disorder (OUD) frequently leave the hospital as patient directed discharges (PDDs) because of untreated withdrawal and pain. Short-acting opioids can complement methadone, buprenorphin...

    Authors: Ashish P. Thakrar, Tanya J. Uritsky, Cara Christopher, Anna Winston, Kaitlin Ronning, Anna Lee Sigueza, Anne Caputo, Rachel McFadden, Jennifer M. Olenik, Jeanmarie Perrone, M. Kit Delgado, Margaret Lowenstein and Peggy Compton
    Citation: Addiction Science & Clinical Practice 2023 18:13
  41. Unhealthy alcohol use (UAU) affects not only the drinking individual, but also significant others (SOs), such as partners and children. Most of the harm to others caused by alcohol can be attributed to common,...

    Authors: Ola Siljeholm and Veronica Ekström
    Citation: Addiction Science & Clinical Practice 2023 18:12
  42. Co-use of stimulants and opioids is rapidly increasing. Randomized clinical trials (RCTs) have established the efficacy of medications for opioid use disorder (MOUD), but stimulant use may decrease the likelih...

    Authors: R. R. Cook, C. Foot, O. A. Arah, K. Humphreys, K. E. Rudolph, S. X. Luo, J. I. Tsui, X. A. Levander and P. T. Korthuis
    Citation: Addiction Science & Clinical Practice 2023 18:11
  43. Many primary care clinicians (PCCs) hold stigma toward people with opioid use disorder (OUD), which may be a barrier to care. Few interventions exist to address PCC stigma toward people with OUD. This study ex...

    Authors: Stephanie A. Hooker, A. Lauren Crain, Amy B. LaFrance, Sheryl Kane, J. Konadu Fokuo, Gavin Bart and Rebecca C. Rossom
    Citation: Addiction Science & Clinical Practice 2023 18:10
  44. Injection drug use-related endocarditis is increasingly common among hospitalized patients in the United States, and associated morbidity and mortality are rising.

    Authors: Hallie Rozansky, Eric Awtry, Zoe M. Weinstein and Alyssa F. Peterkin
    Citation: Addiction Science & Clinical Practice 2023 18:9
  45. Hospitalizations for severe injection drug use-related infections (SIRIs) are characterized by high costs, frequent patient-directed discharge, and high readmission rates. Beyond the health system impacts, the...

    Authors: Belén Hervera, Grace Seo, Tyler S. Bartholomew, Teresa A. Chueng, Edward Suarez, David W. Forrest, Salma Hernandez, Allan E. Rodriguez, Hansel E. Tookes, Susanne Doblecki-Lewis and David P. Serota
    Citation: Addiction Science & Clinical Practice 2023 18:8
  46. Smoking and resulting health problems disproportionately impact low socioeconomic status (SES) individuals. Building resilience presents an approach to ‘closing the gap’. Mindfulness-based interventions and se...

    Authors: Reece De Zylva, Elissa Mortimer, Emma Miller, George Tsourtos, Sharon Lawn, Carlene Wilson, Jonathan Karnon, Richard Woodman and Paul Ward
    Citation: Addiction Science & Clinical Practice 2023 18:7
  47. Identifying patients in primary care services with opioid use disorder and co-occurring mental health disorders is critical to providing treatment. Objectives of this study were to (1) assess the feasibility o...

    Authors: Cristina Murray-Krezan, Alex Dopp, Lina Tarhuni, Mary D. Carmody, Kirsten Becker, Jessica Anderson, Miriam Komaromy, Lisa S. Meredith, Katherine E. Watkins, Katherine Wagner and Kimberly Page
    Citation: Addiction Science & Clinical Practice 2023 18:6
  48. This study examines the impact of the COVID-19 pandemic on work satisfaction, work-related stress, and perceived work quality among substance use treatment providers to better understand challenges faced among...

    Authors: Andrea Fentem, Raven Riordan, Christine Doroshenko, Xiao Li, Erin Kasson, Devin Banks, Rachel P. Winograd and Patricia Cavazos-Rehg
    Citation: Addiction Science & Clinical Practice 2023 18:5
  49. Problematic substance use and Substance Use Disorders (SUD) are common in all layers of the population. Several studies suggest higher prevalence rates of problematic substance use among physicians compared to...

    Authors: Pauline Geuijen, Arnt Schellekens, Aart Schene and Femke Atsma
    Citation: Addiction Science & Clinical Practice 2023 18:4

Affiliated with

Annual Journal Metrics

  • 2022 Citation Impact
    3.7 - 2-year Impact Factor
    4.4 - 5-year Impact Factor
    0.956 - SNIP (Source Normalized Impact per Paper)
    1.166 - SJR (SCImago Journal Rank)

    2023 Speed
    25 days submission to first editorial decision for all manuscripts (Median)
    202 days submission to accept (Median)

    2023 Usage 
    622 Altmetric mentions

Archival content

Addiction Science & Clinical Practice was formerly published by NIDA and previous issues of the journal can be viewed here.